Caricamento...
Following in the footsteps of acute myeloid leukemia: Are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
For most patients with higher-risk myelodysplastic syndromes (HR-MDS) the hypomethylating agents (HMA) azacitidine and decitabine remain the mainstay of therapy. However, the prognosis mostly remains poor and aside from allogeneic hematopoietic stem cell transplantation no curative treatment options...
Salvato in:
| Pubblicato in: | Leuk Lymphoma |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7670856/ https://ncbi.nlm.nih.gov/pubmed/32421403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1761968 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|